1214361-39-3

Basic information

• Product Name: 2-Amino-3-bromo-6-(trifluoromethyl)pyridine
• Synonyms: 2-Amino-3-bromo-6-(trifluoromethyl)pyridine;3-BroMo-6-(trifluoroMethyl)pyridin-2-aMine;3-Bromo-6-(trifluoromethyl)-2-pyridinamine
• CAS NO: 1214361-39-3
• Molecular Formula: C₆H₄BrF₃N₂
• Molecular Weight: 241.0085696
• Mol File: 1214361-39-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Amino-3-bromo-6-(trifluoromethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-3-bromo-6-(trifluoromethyl)pyridine(1214361-39-3)
• EPA Substance Registry System: 2-Amino-3-bromo-6-(trifluoromethyl)pyridine(1214361-39-3)

Safety Data

• Hazardous Substances Data: 1214361-39-3(Hazardous Substances Data)

Usage

General Description

2-Amino-3-bromo-6-(trifluoromethyl)pyridine is a chemical compound with the molecular formula C7H5BrF3N2. It is a heterocyclic aromatic compound containing a pyridine ring with an amino group at position 2, a bromine atom at position 3, and a trifluoromethyl group at position 6. 2-Amino-3-bromo-6-(trifluoromethyl)pyridine is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules. Its unique structure and functional groups make it a valuable intermediate for the development of new drugs and agrochemicals. Additionally, it has potential applications in materials science and as a reagent in organic chemistry reactions.

Upstream product

• 34486-24-3 2-amino-6-(trifluoromethyl)pyridine 

Downstream Products

• 1227515-04-9 2-amino-6-(trifluoromethyl)pyridin-3-ol 
• 2676866-21-8 3-(prop-1-en-2-yl)-6-(trifluoromethyl)pyridin-2-amine 

Relevant articles and documents

Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere

Starting from RO6800020 (1), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC50), pharmacokinetic properties including the free fraction (fraction unbound (fu)) in plasma, and in vivo efficacy. Importantly, we used novel CF3-alkoxy groups as bioisosteric replacements of a fluorinated phenyl ring and properties such as lipophilicity, solubility, metabolic stability, and free fraction could be balanced, maintaining low Pgp efflux needed for CNS penetration. In addition, by reducing aromaticity, we prevented phototoxicity. Additional substitution in the triazolopyridine core disturbed the binding to phosphatidylinositol 4-kinase, catalytic β (PIK4CB). We also introduced less lipophilic head heterocycles devoid of covalent binding (CVB) liability. After these changes, further modifications to the trifluoroethoxy bioisosteric replacement allowed rebalancing of properties, such as lipophilicity, and also potency. Our optimization strategy culminated with in vivo active RO7101556 (18B) having excellent properties and being selected as an advanced candidate.

GAMMA SECRETASE MODULATORS

The invention relates to compounds of formula wherein R1, R1′, R2, R3, n, A, and hetaryl are defined herein or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

HETEROARYL SUBSTITUTED PIPERIDINES

The invention relates to compounds of formula where hetaryl I, hetaryl II, R1,R2,R3, R4, m, n, and o are as defined in the specification or to pharmaceutically active acid addition salts thereof. The compounds of formula I are modulators for amyloid beta and thus may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.